arrow
F

Ferit Aslan

Bitlis Eren University
H指数:5
被引数:86

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study

人表皮生长因子受体2阳性乳腺癌接受帕妥珠单抗为基础的新辅助治疗后病理完全缓解的临床病理预测因素:一项多中心真实世界研究

2026-04-150
OA
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

局部晚期直肠癌中总新辅助疗法的真实世界有效性:一项多中心回顾性研究

2026-03-230
OAAI
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)

在HER2阳性转移性乳腺癌中达到“无疾病证据”的临床意义:土耳其肿瘤学组(TOG)开展的多中心研究

Cancers
IF4.4
2026-03-120
OAAI
Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

葡萄膜黑色素瘤的真实治疗模式和生存率: 土耳其肿瘤学组 (TOG) 的一项多中心队列研究

Cancers
IF4.4
2026-01-280
OA
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study
CANCERS
IF4.4
2025-12-290
OA
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

曲拉妥单抗(sacituzumab govitecan)在伴有转移性或局部晚期不可切除的三阴性乳腺癌患者中的真实世界有效性与安全性:土耳其肿瘤学组(Turkish Oncology Group)开展的一项多中心研究

2025-10-280
PRE
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

FOLFIRINOX:胰腺导管腺癌的最佳辅助治疗?土耳其肿瘤学组(TOG)的多中心研究

2025-08-220
PRE
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
2024-11-300
OAAI
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者中后续治疗的疗效 (第23卷,136,2023)

2023-02-272
OAAI
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者的后续治疗效果

2023-02-1016
OAAI